welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Celecoxib, DFMO combination improved adenoma burden in patients with familial adenomatous polyposis
In a randomized clinical chemoprevention trial, a combination of celecoxib and diflouromethylornithine resulted in a nonsignificant benefit among patients with familial adenomatous polyposis when adenoma count in a defined area was used as the primary endpoint. However, the combination was well tolerated, and a secondary measure of adenoma burden using a video-based global assessment showed a significant incremental benefit.
expertly curated content related to this topic
-
Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps TrialOBJECTIVES: Subjects in the Prevention ...
-
Zane Cohen, MD, FRCS(C)Director - Zane Cohen Centre for Digesti...
-
Effects of Celecoxib on Prostanoid Biosynthesis and Circulating Angiogenesis Proteins in Familial Adenomatous Polypo...Vascular cyclooxygenase (COX)-2-dependen...
-
Is Laparoscopic Surgery an Option to Support Prophylactic Colectomy in Adolescent Patients with Familial Adenomatous...BACKGROUND : Prophylactic surgery is sti...
-
A Study of Guselkumab in Participants With Familial Adenomatous PolyposisThe purpose of this study is to determin...
-
Steven M. Lipkin, MD, PhDDr. Lipkin is a board certified Clinical...